VNVolitionRx Limited VNRX · AMEX
$0.18 -4.40% (-$0.01)
- Market cap
- $2.28M
- Enterprise value
- $11.5M
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 0.9x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- 5,674.4%
- Gross margin
- 89.6%
- Net margin
- -1,043.1%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 1.17
- Free float
- 55.3%
About the company
VolitionRx Limited is a biotechnology company based in Belgium that focuses on the development and commercialization of tests based on epigenetic biomarkers for the diagnosis of various types of cancer and other diseases. Their main product is a test called Nu.QTM, which utilizes nucleosomal biomarker detection technology to determine the presence of cancer in the body. This test is designed to be non-invasive, reliable, and sensitive to various types of cancer, allowing for quick and accurate diagnosis. VolitionRx Limited aims to provide innovative diagnostic tools that can improve the detection of cancer and other diseases in early stages and contribute to better treatment and prognosis for patients.
Sector
Healthcare
Industry
Medical - Devices
CEO
Cameron Reynolds
Employees
57
Headquarters
Henderson
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number